ELGAN Pharma

We named our company ELGAN Pharma, as we are dedicated to improving outcome for babies who are Extremely Low Gestational Age Newborns (ELGANs). This means they are born more than 3 months before term. Premature birth is the number one cause of newborn deaths. With improved standard-of-care worldwide, survival rate increases, leading to the need of improving outcome and quality of life. ELGAN Pharma is a neonatology-focused biotechnology company, dedicated to developing safe tailored therapies to address medical problems and developmental difficulties that are common in babies born very early

Neonatology,biotechnology,pharmaceutical development,pediatrics,retinopathy of prematurity,gastrointestinal therapies,preterm infants ,vision impairement,and late-stage clinical

Elgan pharma operates in the Biotechnology industry.

Elgan pharma's revenue is 11m - 100m

Elgan pharma has 11 - 50 employees.